<DOC>
	<DOCNO>NCT02171585</DOCNO>
	<brief_summary>To investigate whether extent report potent P-gp inhibitor clarithromycin affect pharmacokinetic parameter ( area curve ( AUC ) maximal concentration ( Cmax ) ) dabigatran .</brief_summary>
	<brief_title>Bioavailability Dabigatran With Without Clarithromycin Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Healthy male female ≥18 ≤50 year age , base complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test . Body mass index ( BMI ) range 18.5 29.9 kg/m2 Signed date write informed consent prior admission study accordance GCP local legislation . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackout . Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within 4 week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsade de Pointes ( e.g. , heart failure , hypokalaemia , family history Long QT Syndrome ) In addition , follow exclusion criterion apply female : Pregnancy / positive pregnancy test , plan become pregnant study within 1 month study completion No adequate contraception study 1 month study completion , ( implant , injectables , combine oral contraceptive , intrauterine device , sexual abstinence [ least 1 month prior enrolment ] , vasectomise partner [ vasectomy perform least 1 year prior enrolment ] , surgical sterilisation [ include hysterectomy ] consider adequate contraception . Females whose partner vasectomise , sexually abstinent , surgically sterile ask use barrier contraception method ( e.g . condom , diaphragm spermicide ) Lactation period Intake medication , influence blood coagulation , include acetylsalicylic acid oral vitamin K antagonist , among others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>